Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12453200 | 1.00 | APP (1.00) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL29528164 | 1.00 | APP (1.00) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL13808727 | 0.92 | APP (0.86) | APPMAPTSNCAKDM2B | |
| SCHEMBL17254450 | 0.88 | APP (0.78) | APPMAPTSNCA | |
| SCHEMBL29352045 | 0.88 | APP (0.79) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL951329 | 0.88 | APP (0.79) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL19575131 | 0.88 | APP (0.79) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL21953813 | 0.87 | APP (0.77) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL21697833 | 0.86 | APP (0.76) | APPMAPTSNCA | |
| SCHEMBL21298993 | 0.85 | APP (0.74) | APPMAPTSNCAKDM2BGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746915-A1 | TRIM21-BINDING MOLECULES | United Kingdom Research and Innovation (GB) | 2026-05-27 | — | — | EP | claimed |
| WO-2025224727-A1 | p53 amyloid-binding composition, method, and kit thereof | INDIAN INSTITUTE OF TECHNOLOGY BOMBAY (IN) | 2025-10-30 | — | — | WO | claimed |
| US-20250147049-A1 | METHODS FOR DETECTING CSF TAU SPECIES WITH STAGE AND PROGRESSION OF ALZHEIMER'S DISEASE, AND USE THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025021697-A1 | TRIM21-BINDING MOLECULES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-01-30 | — | — | WO | claimed |
| CN-117355750-A | Methods of detecting CSF TAU substances for the stage and progression of alzheimer's disease and uses thereof | 华盛顿大学 | 2024-01-05 | — | — | CN | claimed |
| EP-4292654-A2 | DETECTION OF MISFOLDED PROTEINS | Board of Regents of the University of Texas System (US) | 2023-12-20 | — | — | EP | claimed |
| EP-4281780-A1 | METHODS FOR DETECTING CSF TAU SPECIES WITH STAGE AND PROGRESSION OF ALZHEIMER DISEASE, AND USE THEREOF | Washington University (US) | 2023-11-29 | — | — | EP | claimed |
| US-11559785-B2 | Method for separation of radioactive sample using monolithic body on microfluidic chip | THE UNIVERSITY OF HULL (GB) | 2023-01-24 | — | — | US | claimed |
| CN-109154671-B | Radioactivity detection | 赫尔大学 | 2022-10-04 | — | — | CN | claimed |
| WO-2022159766-A1 | METHODS FOR DETECTING CSF TAU SPECIES WITH STAGE AND PROGRESSION OF ALZHEIMER DISEASE, AND USE THEREOF | WASHINGTON UNIVERSITY (US) | 2022-07-28 | — | — | WO | claimed |
| EP-3538161-B1 | METHODS FOR MULTI-DOSE SYNTHESIS OF [F-18]FDDNP FOR CLINICAL SETTINGS | UNIV CALIFORNIA (US) | 2022-07-27 | — | — | EP | claimed |
| US-11369955-B2 | Method and apparatus for the analysis of compounds | THE UNIVERSITY OF HULL (GB) | 2022-06-28 | — | — | US | claimed |
| EP-2186782-A1 | Methods for the purification of radiolabelled products using a solid-support scavanger | GE Healthcare Limited (GB) | 2010-05-19 | — | — | EP | claimed |
| US-20080085238-A1 | Small Molecules for Imaging Protein-Protein Interactions | The Government of the United States of America as represented (US) | 2008-04-10 | — | — | US | claimed |
| EP-4746915-A1 | TRIM21-BINDING MOLECULES | United Kingdom Research and Innovation (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12636385-B2 | Selective ligands for tau aggregates | SENTONIX, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260133206-A1 | MISFOLDED PROTEIN DETECTION IN THE EYE | LACRISTAT LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20080085238-A1 | Small Molecules for Imaging Protein-Protein Interactions | The Government of the United States of America as represented (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1418950-B1 | SOLID-PHASE NUCLEOPHILIC FLUORINATION | GE HEALTHCARE LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006083378-A2 | IN VIVO MONITORING OF β-AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085238-A1 | Small Molecules for Imaging Protein-Protein Interactions | HSPBP1, HSPA2, HSPA8 | APP 36/4885MAPT 50/4885SNCA 427/4885 |
| US-12636385-B2 | Selective ligands for tau aggregates | MAPT, PSEN2, PSEN1 | APP 36/4885MAPT 1/4885SNCA 21/4885 |
| US-20260133206-A1 | MISFOLDED PROTEIN DETECTION IN THE EYE | SNCA, SAAL1, PRNP | APP 4/4885MAPT 11/4885SNCA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.